Decreased brain serotonin transporter binding in the euthymic state of bipolar I but not bipolar II disorder: a SPECT study.
OBJECTIVE
Previous positron emission tomography studies have demonstrated that serotonin transporter (SERT) binding in the midbrain is decreased in the depressive state of bipolar disorder (BD). The aim of this study was to assess SERT binding in the midbrain of patients in a euthymic state of BD.


METHODS
Twenty-eight healthy controls and 24 patients in a euthymic state of medicated BD were recruited. Euthymic state was defined as Montgomery-Asberg Depression Rating Scale scores < 10 and Young Mania Rating Scale scores < 7 within a consecutive eight-week period. Single photon emission computed tomography with the radiotracer (123)I-ADAM was used to measure SERT binding in the midbrain. An equilibrium ratio model was used for data analysis. Specific uptake ratio (SUR), which represents availability of SERT binding in the midbrain, was the primary measurement outcome.


RESULTS
The averaged SURs were not different between healthy controls and BD patients in euthymic state (p = 0.27). However, a three-way ANCOVA analysis comparing SURs in healthy controls, bipolar I disorder (BD I) patients, and bipolar II disorder (BD II) patients, covarying education duration and sex, showed that the averaged SURs were significantly lower in BD I than BD II patients and healthy controls (p = 0.042). The decreased SURs in BD I patients were well correlated with duration of illness (R = -0.742, p = 0.014) only.


CONCLUSIONS
Our findings demonstrate that there is differential biological regulation in BD I and BD II patients after stable treatment, which may support the existence of a dichotomy in BD.
Chou
Yuan-Hwa
YH
Department of Psychiatry, Taipei Veterans General Hospital and National Yang Ming University, Taipei, Taiwan. c520608@ms64.hinet.net
Wang
Shyh-Jen
SJ
Lin
Chun-Lung
CL
Mao
Wei-Chung
WC
Lee
Shin-Min
SM
Liao
Mei-Hsiu
MH
D000704:Analysis of Variance; D000928:Antidepressive Agents / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000494:pharmacology; D001714:Bipolar Disorder / Q000145:classification / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism*; D002928:Cinanserin / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D006801:Humans; D007457:Iodine Radioisotopes; D008279:Magnetic Resonance Imaging / Q000379:methods; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D011569:Psychiatric Status Rating Scales; D012702:Serotonin Antagonists / Q000493:pharmacokinetics; D050486:Serotonin Plasma Membrane Transport Proteins / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods
C413491:2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D007457:Iodine Radioisotopes; D012702:Serotonin Antagonists; D050486:Serotonin Plasma Membrane Transport Proteins; D002928:Cinanserin